HomeAI · summaries
Storia in 4 fonti
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Clinical Success Is No Longer One Number
By Andreas Dimakakos Director of Clinical Data, Kate Smietana Director, Knowledge and Thought Leadership, Panos Karelis VP of Commercial, Dimitris Skaltsas Co-founder & CEO | In…
- ·
Cellares' recent automated cell therapy wins have 'opened the biotech floodgates'
After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have opened for Cellares, the automated cell therapy…
- ·
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients…
- ·
morningstar.com
Correction to Celcuity Gets FDA Approval Headline
Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast Cancer Drug," at 5:33 p.m. ET, misspelled the company…
- ·
biopharmadive.com
Celcuity gains FDA approval for closely watched breast cancer drug
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
- ·
statnews.com
Celcuity's breast cancer drug approved, its first
FDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The Readout